Mutant p53
ATP
DNA damage
MortaparibPlus
PARP1 hyperactivation
luminal-A breast cancer cells
mortalin–p53 interaction
tumor suppression
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Jun 2021
18 Jun 2021
Historique:
received:
07
04
2021
revised:
03
06
2021
accepted:
14
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
We previously performed a drug screening to identify a potential inhibitor of mortalin-p53 interaction. In four rounds of screenings based on the shift in mortalin immunostaining pattern from perinuclear to pan-cytoplasmic and nuclear enrichment of p53, we had identified Mortaparib
Identifiants
pubmed: 34207240
pii: cancers13123043
doi: 10.3390/cancers13123043
pmc: PMC8234533
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Protein Pept Lett. 2009;16(5):517-29
pubmed: 19442231
Biochem Pharmacol. 2014 Nov 1;92(1):157-63
pubmed: 24976506
Am J Pathol. 2006 May;168(5):1526-30
pubmed: 16651619
Br J Pharmacol. 2014 Apr;171(8):2000-16
pubmed: 24684389
Sci Rep. 2017 Feb 06;7:42016
pubmed: 28165047
Drugs Context. 2018 Aug 08;7:212540
pubmed: 30116283
Cell Death Differ. 2011 Jun;18(6):1046-56
pubmed: 21233847
Exp Gerontol. 2007 Apr;42(4):263-74
pubmed: 17188442
Int J Biochem Cell Biol. 2012 Mar;44(3):496-504
pubmed: 22155302
Nat Genet. 2008 Jul;40(7):807-8; author reply 810-2
pubmed: 18583965
PLoS One. 2015 Sep 16;10(9):e0138192
pubmed: 26376435
Cell Stress Chaperones. 2002 Jul;7(3):309-16
pubmed: 12482206
Breast Cancer Res Treat. 2019 Feb;173(3):489-497
pubmed: 30382472
Ann N Y Acad Sci. 2008 Dec;1147:233-41
pubmed: 19076445
Apoptosis. 2002 Aug;7(4):321-8
pubmed: 12101391
Elife. 2020 Oct 14;9:
pubmed: 33052098
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18308-13
pubmed: 17116882
J Exp Clin Cancer Res. 2019 Dec 19;38(1):499
pubmed: 31856867
Curr Mol Med. 2013 Sep;13(8):1229-40
pubmed: 23865427
Breast Cancer Res Treat. 2011 Jun;127(2):345-55
pubmed: 20556506
Clin Cancer Res. 2007 Apr 1;13(7):2298-306
pubmed: 17404115
Biochem Biophys Res Commun. 2012 Jun 29;423(2):411-6
pubmed: 22683628
Nat Cell Biol. 2001 Sep;3(9):839-43
pubmed: 11533664
NPJ Breast Cancer. 2019 Aug 2;5:21
pubmed: 31396557
Clin Cancer Res. 2018 Oct 1;24(19):4887-4899
pubmed: 29793947
Cancer Chemother Pharmacol. 2000;46(5):343-50
pubmed: 11127937
Breast Care (Basel). 2013 May;8(2):102-9
pubmed: 24000280
J Biol Chem. 1998 Nov 6;273(45):29586-91
pubmed: 9792667
Histol Histopathol. 2002 Oct;17(4):1173-7
pubmed: 12371145
Biomolecules. 2012 Mar 01;2(1):143-64
pubmed: 24970131
Oncogene. 2003 Oct 2;22(43):6669-78
pubmed: 14555980
PLoS One. 2009 Jul 03;4(7):e6146
pubmed: 19582160
Int J Oncol. 2018 Mar;52(3):925-932
pubmed: 29393408
Br J Cancer. 2009 Nov 3;101(9):1606-12
pubmed: 19773755
Int J Cancer. 2006 Jun 15;118(12):2973-80
pubmed: 16425258
Nat Rev Mol Cell Biol. 2017 Oct;18(10):610-621
pubmed: 28676700
Int J Cancer. 2020 Aug 15;147(4):1086-1097
pubmed: 31845320
J Pathol. 2005 Jan;205(1):74-81
pubmed: 15532096
Cancers (Basel). 2021 Feb 17;13(4):
pubmed: 33671256
Invest New Drugs. 1990 Nov;8(4):347-54
pubmed: 2084068
Breast Cancer Res. 2002;4(2):70-6
pubmed: 11879567
Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22609-22618
pubmed: 31591209
Cancer Treat Rev. 2012 Oct;38(6):698-707
pubmed: 22178455
Endocr Relat Cancer. 2004 Dec;11(4):643-58
pubmed: 15613444
Cancer Res. 2016 Mar 9;76(9):2754-2765
pubmed: 26960973
Cancer Res. 2000 Dec 15;60(24):6818-21
pubmed: 11156371
Cell Chem Biol. 2018 Oct 18;25(10):1219-1230.e3
pubmed: 30057300
J Biol Chem. 1993 Mar 25;268(9):6615-21
pubmed: 8454632
ACS Chem Biol. 2013;8(6):1311-23
pubmed: 23570531